Nivolumab, Docetaxel, and ADT Triplet Confers Antitumor Activity in mCRPC Regardless of Prior NAT Use
Karim Fizazi, MD, PhD, presents final analysis results from arm B of the phase 2 CheckMate 9KD trial.
Urology Conferences
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Survival Trends Analysis Shows Significant OS Gains for MIBC, But Not Urothelial Carcinoma
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Radium-223/Enzalutamide Combination Therapy Could Improve Outcomes in Progressive mCRPC
Kessel et al present the final efficacy and safety results from a phase 2 study of radium-223 plus enzalutamide vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer (mCRPC).
COVID-19 Adversely Affecting Patients With Genitourinary Cancers
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Adding a First-Generation Anti-Androgen to ADT for mCSPC Does Not Improve Outcomes
Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration-sensitive prostate cancer.
High CTC Counts Predict Increased Progression, Mortality Risk in mHSPC
Investigators say they believe their study is the first to show a link between circulating tumor cell counts and progression-free and overall survival in men with metastatic hormone-sensitive prostate cancer.
-
Loading...
-
Loading...
Next post in Genitourinary Cancers Symposium
